TR1 Notification of Major Interest
Tuesday, March 21, 2017 - 11:51

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has today received a TR-1 by Aviva plc (“Aviva”). Aviva’s holding in ImmuPharma is now confirmed at a total of 10,280,516 Ordinary Shares which equates to a current position in the Company of 7.76% of ImmuPharma’s total voting rights figure of 132,522,985 Ordinary Shares.

 For full disclosure of the TR1 click here.